Journal article
Precision medicine for advanced pancreas cancer: The individualized molecular pancreatic cancer therapy (IMPaCT) Trial
LA Chantrill, AM Nagrial, C Watson, AL Johns, M Martyn-Smith, S Simpson, S Mead, MD Jones, JS Samra, AJ Gill, N Watson, VT Chin, JL Humphris, A Chou, B Brown, A Morey, M Pajic, SM Grimmond, DK Chang, D Thomas Show all
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2015
Abstract
Purpose: Personalized medicine strategies using genomic profiling are particularly pertinent for pancreas cancer. The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial was initially designed to exploit results from genome sequencing of pancreatic cancer under the auspices of the International Cancer Genome Consortium (ICGC) in Australia. Sequencing revealed small subsets of patients with aberrations in their tumor genome that could be targeted with currently available therapies. Experimental Design: The pilot stage of the IMPaCT trial assessed the feasibility of acquiring suitable tumor specimens for molecular analysis and returning high-quality actionable genomic data within..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia (NHMRC)
Awarded by Cancer Council NSW
Awarded by Cancer Institute NSW
Funding Acknowledgements
This study was supported by the National Health and Medical Research Council of Australia (NHMRC; 631701, 535903, 427601); Cancer Council NSW (grant numbers SRP06-01, SRP11-01); Avner Nahmani Pancreatic Cancer Foundation; Cancer Institute NSW(grant numbers 06/ECF/1-24, 09/CDF/2-40, 07/CDF/1-03, 10/CRF/1-01, 08/RSA/1-15, 07/CDF/1-28, 10/CDF/2-26,10/FRL/2-03, 06/RSA/1-05, 09/RIG/1-02, 10/TPG/1-04, 11/REG/1-10, and 11/CDF/3-26); R.T. Hall Trust; Petre Foundation; Philip Hemstritch Foundation; and Sydney Catalyst, University of Sydney, Australia.